Psoriasis is a chronic inflammatory disease with complex pathogenesis. There is growing evidence that excess body fat can lead to systemic inflammation, which exacerbates the symptoms of the disease. The aim of this study was to review the available scientific literature on the use of GLP-1 receptor agonists in the treatment of psoriasis. Their mechanism of action not only includes better glycaemic control, weight loss and reduction of inflammation, but also has a significant effect on the immune response of T lymphocytes, NK cells and macrophages. Despite small study groups and a short observation period, the available clinical studies show a reduction in the PASI index and inflammatory markers, with the positive therapeutic effect being most noticeable in patients with obesity and type 2 diabetes. GLP-1 receptor agonists are a promising therapeutic pathway for the treatment of psoriasis, especially in patients with metabolic disorders. Unfortunately, further long-term clinical trials involving a larger number of subjects are needed to confirm the efficacy and safety of this form of treatment.
Majda et al. (Wed,) studied this question.